Oslo, 9 September 2024: The board of directors of Navamedic ASA (the “Company”), has today, on 9 September 2024, in accordance with the authorisation granted to it by the general meeting on 4 June 2024, resolved to increase the Company’s share capital by NOK 170,200 by issuance of 230,000 new shares, each with a nominal value of NOK 0.74, in order to facilitate the settlement of exercise of 230,000 share options. The exercise price is NOK 19.00 per share for the 230,000 new shares.

Following the registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret), the new share capital of the Company will be NOK 13,070,454.98, divided into 17,662,777 shares, each with a nominal value of NOK 0.74. The share capital increase will be registered with the Norwegian Register of Business Enterprises as soon as practically possible after the share contribution has been fully paid.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA:

Navamedic ASA is a Nordic full-service provider of high-quality products to hospitals and through pharmacies. Navamedic meets the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA).

For more information, please visit www.navamedic.com.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.